Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Palbociclib|DRUG: Letrozole
Sponsor: SOLTI Breast Cancer Research Group
Collaborators: Pfizer